Thermo Fisher Scientific to Invest USD 150 Million to Expand Pharma Services Capabilities

Thermo Fisher Scientific Inc., the world leader in serving science, announced that it is investing USD 150 million in its Pharma Services business to provide additional capacity for sterile liquid and lyophilized product development and commercial manufacturing. Included in the site expansion projects are Monza and Ferentino, Italy, and Greenville, North Carolina. In response to customer requests, each of the sites will be equipped with aseptic filling lines and isolator technology. Construction is expected to be completed within the next 24 months. “These investments will help expand our global sterile manufacturing network and meet the increasing demand from customers that rely on our biologics development and manufacturing expertise,” said Michel Lagarde, president of pharma services for Thermo Fisher Scientific. “We continue to invest to expand our capabilities and help our customers deliver the highest quality medicines to the patients who need them.” – Medical Buyer Bureau

Share this:

Related Post

Stay Updated on Medical Equipment and Devices industry.
Receive our Daily Newsletter.